Weight-loss and Diabetes Drugs Associated with Rare Eye Conditions and Vision Risks

Recent studies suggest that GLP-1 agonists like Ozempic and Wegovy may slightly increase the risk of serious eye conditions such as NAION and diabetic retinopathy, but they also offer significant benefits for managing diabetes and obesity. Regular eye exams and careful risk assessment are recommended for users, especially those with pre-existing risk factors. Ongoing research aims to better understand these risks and improve patient safety.